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1. Introduction 
According to the chemical carcinogenesis hypothesis (Husgafvel-Pursiainen, 2004) (Loeb & 
Harris, 2008) chemical carcinogens exert their activity by penetrating cells, cell nuclei and 
interact with DNA generating DNA lesions such as single- or double-strand DNA breaks 
and DNA base modifications (adduction, substitution, base oxidation). DNA lesions when 
not removed are fixed as DNA mutations. Mutations as alterations of DNA structure are 
responsible for a change of the genetic information and the same remain the key step in 
carcinogenic transformation of cells. The whole process of carcinogens metabolism in a cell 
proceeds under enzymatic control (Fig.1). The first step known as metabolic activation 
provides changes in carcinogen molecule into better solubility and higher reactivity with 
detoxifying enzymes. Only few chemical carcinogens can omit this step and react directly 
with the enzymes. The second step being a detoxification proper consists of enzymatic 
conjugation of activated carcinogens and removal carcinogen metabolites out of a cell. This 
step is highly efficient and usually over 90% of exogenous compounds are being removed. 
At this stage the activated carcinogens are capable to react with DNA but still detoxification 
remains the main pathway when a reactivity towards DNA is less likely. Generation of 
DNA lesions is automatically followed by DNA repair. 
The process of DNA repair is recognized as the last line of a cell defense against 
mutagens/carcinogens. DNA repair is carried into effect on separate pathways adjusted to a 
type and extent of DNA damage, and the cell cycle (Jenkins et al., 2010). A most commonly 
accepted categorization of DNA repair mechanisms is shown in Table 1. To comment a 
multitude of DNA repair mechanisms, a direct repair, DNA excision repair and 
recombination repair are specialized in dealing with various types of DNA lesions at first 
instance. Mismatch DNA repair pathway works later to remove DNA lesions remaining 
after processing by the above mentioned mechanisms or emerge late in the cell cycle. 
Recombination repair is involved both in DNA and chromosome repair. SOS-repair acts 
only when DNA lesions occur abundantly. 
There are roughly 4000 chemical compounds occurring in tobacco smoke. Carcinogenic 
properties were attributed up to 60 constituents carcinogenic properties. The main 
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carcinogens of tobacco smoke are: polycyclic aromatic compounds (with benzo/a/pyrene as 
the best known example), aromatic amines, N-nitrosamines and reactive oxygen species 
(Talhout et al., 2011). The molecular aspects of carcinogenesis generated by tobacco smoke is 
relatively well recognized (Hecht, 2003; Husgafvel-Pursiainen, 2004). Lesions generated by 
tobacco smoke carcinogens include single-strand DNA breaks, adducts carcinogen:DNA 
and oxidative DNA damage. Any preference to a specific DNA sequence was not 
established. Anyway, guanosine residue was found to be the most sensitive DNA element 
for carcinogen attack. Regardless a lack of sequence specificity an attention was focused on 
lesions generated in cancer-related genes. TP53 lesions and mutation were studied most 
efficiently. A direct relation between benzo/a/pyrene:guanosine adducts formation 
generating later on G:C to T:A mutations was proven in the case of TP53 (Denissenko, 1996). 
Further, studying cancer-related genes a pattern of mutations derived from tobacco smoke 
exposure was identified in TP53 and other genes (Le Calvez et al., 2005). 
 
Fig. 1. Carcinogen metabolic pathways and health effects. 
An epidemiological evidence for a causative contribution of tobacco smoking to cancer of 
lung or larynx as well as an increased risk to develop many types of cancers among tobacco 
smokers has been provided long ago (Vineis et al., 2004). A strong association between 
tobacco smoking and cancer risk leads to an opinion on predominance of exogenous factors 
over genetic background (Le Marchand, 2005). On the other hand, only a minority of 
smokers develop any type of cancer. Hence, it was deduced that a combination of 
exogenous exposure and individual predisposition is responsible for carcinogenic 
transformation (Taioli, 2008). An extensive review of cancer genes divided into contributing  
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Type Subtype Comment 
Direct repair  restricted to a few lesions 
Excision repair 
Base excision repair (BER) removes majority of lesions 
Nucleotide excision repair 
(NER) 
as above 
Recombination repair 
Homologous end joining 
repair of DNA and 
chromosomes 
Non-homologous end joining as above 
Mismatch repair  
specialized in removal 
mispairing of DNA bases 
 Transcription-coupled repair 
preference for actively 
transcribed genes, fast 
 Global repair slow repair of overall genome 
SOS repair  mutation-prone system 
FA Homologous recombination ICL removal 
Table 1. Classification of DNA repair pathways. 
to cancer risk and connected with cancer progression was written by Vogelstein and Kinzler 
(2004). An impact of genetic factor on health effects of tobacco smoking was also discussed 
more specifically in relation to head and neck cancer (Badawy et al., 2008; Rossing, 1998). As 
such specific genes as BRCA1 or APC involved in breast and colon cancer, respectively, were 
not discovered in head and neck cancer, an attention was paid on so-called “low-
penetration” genes, mainly those involved in carcinogens processing. Within the group of 
low-penetration genes a potential significance of DNA repair genes was admitted (Livneh et 
al., 2005). The latter author points at the key function of DNA repair that is removal or by-
pass the damaged sites to restore the original structure and function. 
2. Genotype versus phenotype 
A comparison of tumor cells with normal cells has shown that the level of damage is higher 
in neoplastic cells. An observation was applicable to various types of damage including 
single-strand DNA breaks, carcinogen:DNA adducts, DNA mutations, chromosome 
aberrations and others. Next, an observation was extended also on other cells including 
peripheral blood lymphocytes derived from cancer subjects compared to those from healthy 
individuals. The latter observation has got a substantial significance as blood lymphocytes 
are commonly used as a surrogate material for biological analysis obtainable on non-
invasive way (Phillips, 2005). However, the early results concerning a high level of DNA 
lesions and chromosome aberrations in cancer subjects posed a fundamental question 
concerning a role of former exposure to carcinogens confronted with an impaired DNA 
repair. Although some papers ignored an impact of DNA repair, their authors brought into 
light a differentiation between active and passive smoking as a source of carcinogens 
(Phillips, 2002), location of an organ exposed (Hainaut, Olivier, & Pfeifer, 2001) or exposure 
threshold (Jenkins et al., 2010). 
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On the other hand an early paper from M.R. Spitz group (Wei, Cheng, Hong, & Spitz, 1996) 
dealed with DNA repair in lung cancer subjects. DNA repair capacity was estimated in 
peripheral blood lymphocytes using host-cell reactivation assay, which measures cellular 
reactivation of a reporter gene damage to exposure to activated benzo/a/pyrene. The mean 
level of DNA repair was significantly lower in subjects than in controls. The final conclusion 
was that individuals with reduced DNA repair level are at an increased risk to develop lung 
cancer. Applying the same method the study was repeated on head and neck subjects. A 
reduced DNA repair capacity was shown when 55 newly diagnosed, untreated head and 
neck subjects were compared to 61 healthy controls (Cheng et al., 1998). 
Following years have provided several papers documenting impairment of DNA repair 
potential in association with cancer. Alternative methods were shown to be useful to study 
DNA repair impairment. Schmezer et al. (2001) applied comet assay to study bleomycin-
induced damage in peripheral blood lymphocytes. Lung cancer blood donors (100 cases) 
were found more sensitive for such damage in comparison with healthy donors (110). High 
mutagen sensitivity in cancer subjects was explained as resulted from significantly reduced 
DNA repair capacity. The paper contains also interesting technical remarks. The authors 
demonstrated applicability of cryo-preserved lymphocytes to estimate DNA repair up to 12 
months after blood collection. A similar experimental attempt was used in our own studies 
(Gajecka et al., 2005). A higher level of spontaneous and benzo/a/pyrene-induced was 
shown by comet assay in peripheral blood lymphocytes derived from laryngeal cancer 
subjects compared with healthy donors (52 cases v. 54 controls). A level of spontaneous 
DNA damage tended to increase with tumor grading. The latter result was not confirmed by 
the analogical study (L. E. Wang et al. 2010) done on much bigger group (744 head and neck 
subjects v. 753 matched cancer-free controls). The conclusion of Wang et al. was that the 
reduced removal of tobacco smoke-induced DNA adducts contributes to the risk of head 
and neck cancer but does not influence tumor characteristics. However, our results taken as 
”phenotype” were apparent. Then, we attempted to explain them by distribution of so-
called “risk” and “protection” genotypes of XPD, XRCC1 and XRCC3 genotypes of DNA 
repair genes. The distribution differences did not reach the level of statistical significance 
that means that phenotype-genotype correlation was poor. Still, phenotypic deficit of DNA 
repair was only partly confirmed by overrepresentation of “risk” genotypes of the studied 
DNA repair genes. Again, an impairment of DNA repair was shown in head and neck 
cancer cells taken from tissue biopsies compared to peripheral blood lymphocytes of healthy 
controls exposed to hydrogen peroxide treated taken as a model genotoxicant (47 cases v. 38 
healthy controls). An advanced comet assay permitted for estimation of single-strand DNA 
breaks, oxidative lesions and efficiency of DNA repair. Besides, a general deficit of DNA 
repair, the authors established that H2O2-induced lesions were repaired less effectively in 
cancer cells from patients with metastasis than from those without metastasis  
(Rusin et al., 2009). 
The most direct way to understand a link between DNA repair deficit and head and neck 
cancer are studies on processing of tobacco smoke lesions and their removal (Hecht, 2003; L. 
E. Wang et al., 2010; Wei et al., 1996). Polycyclic aromatic hydrocarbons are represented by 
several compounds present in tobacco smoke and generate a variety of carcinogen: DNA 
adducts. The structural features of the PHA-adducts play a role in differential repair of these 
adducts. Although PAH:DNA adducts are repaired dominantly by nucleotide excision 
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repair (NER) pathway, differences in repair efficiency still occur for individual DNA 
adducts removal (Zhong et al., 2010). At this point it is necessary to remind that DNA 
lesions not removed fast enough are most harmful for a cell. 
It was already mentioned that another type of DNA lesions generated by tobacco smoke is 
oxidative DNA damage. The major mechanism for repair of oxidized DNA bases 
represented by 8-oxoguanine is base excision repair (BER), but nucleotide excision repair 
seems to be involved too. It has been shown in lung cancer that the enzymes involved in 
recognition of oxidative DNA damage alter their activity and, in turn affect tumor growth 
because of increased formation of apurinic sites in DNA (Radak et al., 2005). The question of 
alterations of oxidative DNA damage repair which leads to accumulation of oxidative DNA 
lesions, mutagenesis and cancer development was reviewed recently (D'Errico, Parlanti, & 
Dogliotti, 2008). 
In head and neck cancer one of the most disregulated genes is epidermal growth factor 
receptor overexpressed in ca. 90% cases. Reiter et al. (2010) undertook a study to explain a 
reason of EGFR overexpression in terms of sensitivity to mutagens and DNA repair 
potential. Oropharyngeal cancer cells were exposed to activated benzo/a/pyrene in vitro. 
Unexpectingly, an extent of damage was comparable in EGFR gene locus and in 
chromosome centromere, as well as in non-tumor tissue control. Also DNA repair capacity 
was comparable in all experiments. It looks, nor EGFR gene amplification, neither DNA 
repair might have a moderate effect on protein over-expression. 
3. Evidence from genetic polymorphism 
Variation in DNA repair as a factor in cancer susceptibility was associated early with 
single nucleotide polymorphism (SNP). Many gene variants are common in human 
population. Some structural variants decreasing a capacity to repair DNA were found 
more frequently in cancer cases and could be recognized as “risk” variants. The extreme 
case of DNA repair deficiency was established in a few rare diseases where DNA repair 
defect was followed by over-frequent tendency to develop cancer (Tab. 2). Gene variants 
working opposite way would be known as “protective” variants. Such attribution is not 
having a universal character because of ethnic differences in gene variants distribution 
(Becker, Nieters, & Rittgen, 2003; Mohrenweiser & Jones, 1998). Though, the mechanisms 
dominantly involved in their repair of tobacco smoke-induced lesions are: base-excision 
repair (BER), nucleotide excision repair (NER) followed by recombination repair and 
mismatch repair, it was assumed that impairment of DNA repair process, particularly in 
the key pathways would contribute to the increased risk of head and cancer. This 
assumption is workable within the hypothesis of chemical carcinogenesis but a connection 
with the hypothesis on cancer stem cells (Sales, Winslet, & Seifalian, 2007) is not excluded. 
At this point one had to stress that the working material for studies on genetic 
polymorphisms are blood cells as all the cells of the organism have the same genetic 
information not changed throughout their ontology. 
Establishing a link between single nucleotide polymorphism, distribution of gene variants 
and cancer risk was followed by publication of plethora of papers. Very early papers deal 
usually with an involvement of one repair gene/enzyme. The good example is a paper of  
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Disease Main genes identified Cancer preference 
Xeroderma pigmentosum 
XPA, XPC, XPD, XP-
variant 
skin 
Ataxia telangiestasia ATM breast, other sites 
Cockayne’s syndrome ERCC6 (CSB), ERCC8  
Bloom’s syndrome BLM 
Broad spectrum of cancer 
predisposition 
Fanconi’s Anemia 
14 FA genes (listed 
below) 
AML, head and neck, 
breast, gyneaological 
cancers 
Trichothiodystrophy XPD skin 
Table 2. Major diseases associated with DNA repair deficit. 
Sturgis et al., (1999) describing an analysis of X-ray cross-complementing group one 
(XRCC1) gene polymorphism in relation to head and neck risk. The XRCC1 gene 
participates in base excision repair (BER) by encoding a protein acting in the repair of single-
strand DNA breaks. Two different polymorphisms of XRCC1 were studied in the group of 
203 cancer cases v. 425 controls. Distribution of gene variants did not vary considerably 
between the groups but XRCC1 26304T allele was found as a risk factor. The same group 
(Ho et al., 2007) studied also polymorphism of the same gene as a risk factor of salivary 
gland carcinomas. Three groups of samples were collected: 138 salivary gland carcinomas, 
50 benign gland tumor and 503 cancer-free controls. It was established that XRCC1 1915C 
allele was associated with a lower risk and XRCC1 194Trp allele with a higher risk of 
salivary gland carcinoma. A much broader character had a study of Hao et al. (2004) on gene 
polymorphism connected with BER mechanism of DNA repair. There have studied 129 
SNPs in the eight BER genes including ERCC1. An estimation of distribution of gene 
variants in Chinese cohort (419 esophageal cancer subjects v. 480 healthy controls) pointed 
at four gene variants including XRCC1-77C allele as predictors of an increased risk. 
Esophageal cancer does not belong formally to head and neck cancer group but anatomical 
vicinity and histological classification as squamous cell carcinoma allows for a close 
analogy. Interestingly, analogical on a large cohort of breast cancer (over 20 000 cases v. 
comparative number of controls) established only a moderate influence of one of three 
studied polymorphism on breast cancer in Asians and Africans but not in Caucasians (Y. 
Huang, Li, & Yu, 2009). 
Investigation of gene polymorphism in nucleotide excision repair (NER) attracted many 
research groups. The studies were focused on XPD that is an evolutionary conserved ATP-
dependent helicase, responsible for unwinding DNA molecule and removal of bulky 
carcinogen:DNA adducts. Structure-activity relationship of polymorphic gene variants of 
XPD was already established and described with considerations on its impact of cancer risk 
(Lunn et al., 2000). Previously shown reduced DNA repair capacity in head and neck cancer 
subjects together with removal of tobacco smoke-derived DNA adducts by XPD allowed to 
expect a key role of this gene in risk modulation. In line with this expectation Sturgis et al. 
(2000) studied a distribution of two polymorphisms of XPD in 189 head and neck subjects 
and 496 cancer-free controls. All subjects were non-Hispanic whites. A frequency of XPD 
22541A variant did not differ enough to influence a relative risk. For XPD 39531C a 
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moderate increase of risk was established. The latter polymorphism was studied also on 
Swedish cohort consisting of 185 lung cancer cases v. 162 matched controls. The conclusion 
of the study was that the XPD variant alleles may by associated with a reduced repair of 
aromatic DNA adducts and increase lung cancer risk (Hou et al., 2002). The results of Hou et 
al.  were fully confirmed in another study done on Chinese cohort (135 cancer cases v. 152 
controls) targeting for esophageal squamous cell carcinoma (Yu et al., 2004). However, a 
meta-analysis of genetic polymorphism of three genes involved in NER (namely: ERCC1, 
XPD and XPG) provided some skepticism about their role. The authors concluded that 
fluctuation of variant frequency and their association with cancer risk will probably be 
minimal (Kiyohara & Yoshimasu, 2007). As the published results did not meet expectation it 
attracted to search for other polymorphism not known yet. An example is the paper by 
Kumar et al. (Kumar, Angelini, & Hemminki, 2003), who discovered a novel intronic 
mutation in the XPD gene.  
Hence, further studies were aiming for a parallel coincidence of gene defect, gene-gene 
and gene-environment interaction. The genes most commonly studied for a joint effect 
were XRCC1, XRCC3 and XPD, representing different DNA repair pathways, namely: 
BER, NER and recombination repair, respectively. Such attempt was used by Matullo et 
al. (2003) to estimate effect of three polymorphisms in XRCC1 exon 10, XPD exon 23 and 
XRCC3 exon 7. Distribution of gene variants was assessed in 628 Italian healthy 
individuals and confronted with the level of aromatic DNA adducts in blood 
lymphocytes. A dose-response relationship between the number of risk variants and DNA 
adduct level. The interpretation was that the combined effect of multiple variant alleles 
modulates DNA repair capacity. The same trio of DNA repair genes supplanted by 
MGMT (enzyme coded by MGMT is repairing O6-alkylguanine adducts) was analyzed in 
555 head and neck cancer cases v. 792 controls. Ethnic differences were found. XRCC1 
Gln399Gln was associated with decreased risk in whites, but XPD 751 and XRCC3 241 did 
not change cancer risk. (W. Y. Huang et al., 2005). 
Extension of a list of genes and their polymorphisms was done by De Ruyck et al. (2007) by 
an analysis (110 lung cancer v. 110 non-cancer controls) of 10 polymorphisms of genes 
involved in BER (XRCC1, APE1, OGG1, XPA, XPC and XPD). Primary significance was 
attributed to APE1 Asp148Glu, and the secondary one to XRCC1 ArgGln and XPD 
Lys751Gln concerning conversion of tobacco smoking effects into lung cancer. At this point 
it is necessary to admit the papers claiming no measurable effect of DNA repair genes 
polymorphism on cancer risk (London et al., 2001). 
Because of a lack of convincing results concerning an impact of individual gene variants 
in cancer risk, recent years there is a tendency to study in parallel experiments a series of 
genes and multiple polymorphisms. Also a study groups tend to gain high numbers to get 
a reasonable statistic power. Within it a meta-analysis of previously published results 
plays an important role. An example of such situation is a paper Michiels et al. (Michiels 
et al., 2007) who studied polymorphism in 70 genes in lung cancer, head and neck cancer 
and healthy Caucasian individuals. None of the studied genes BER- or NER-associated 
genes was found to be associated individually with an influence of head and neck risk. 
Contrary, a few alleles of the genes attributed to DNA replication, translesion synthesis 
and transcription appeared to change a genetic risk. An international team anchored at 
International Agency for Research on Cancer, Lyon, France, presented an analysis of 28  
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SNPs in 18 DNA repair genes 9 SNPs in 7 cell cycle control genes on 811 cases with the 
upper aerodigestive tract v. 1083 individuals not related to tobacco and alcohol. In DNA 
repair genes only two variant alleles of MGMT and one allele of OGG1 were found 
moderately more frequently in cases, whilst only three alleles including XPA variant were 
associated with a protective effect. The authors discuss a false positive results present in 
papers based on small study groups an postulate further extension of a number of 
individual include into study (Hall et al., 2007). Under the same auspices another broad 
analysis was done in connection with the upper aerodigestive tract (Canova et al., 2009). 
Studying the material derived from 10 European countries including 1511 cancer cases and 
1457 controls the authors analyzed 115 SNPs from 62 genes already known to be associated 
with cancer. In 22 SNPs of DNA repair genes only three were found statistically significantly 
reducing the risk. The results are meaningful as that time it was the largest genetic 
epidemiologic study on the upper aerodigestive tract in Europe. Almost the same time there 
was published a large analysis of genetic polymorphism in breast cancer (Smith et al.,2010). 
Distribution of gene variants derived from 18 SNPs was estimated in 336 cases v. 416 
controls (all Caucasians). An impact of individual genes only three cases reached a level of 
significance. The authors suggest (i) to perform combine SNPs analysis (polygenic model) 
and (ii) to increase the sample size. 
Altogether, the hypothesis of a significant impact of polymorphism of DNA repair genes 
besides many research efforts was not sufficiently proven but it does not eliminate DNA 
repair from cancer risk estimation. Its moderate effect was shown and a necessity of gene-
gene interaction was suggested. 
4. Specific types of cancer 
To unravel a link between DNA repair and risk of cancer an alternative way of studies 
explores sub-classification of cancer to eliminate potential differences connected with 
etiology, histology, progression and other factors. 
Rodriguez et al. (2007) restricted their interest to the early oral squamous cell carcinoma on 
one site, and on MGMT, that protects against alkylating mutagens repairing DNA in BER 
pathway. Working on protein level they observed a loss of MGMT protein expression from 
leukoplakia to early oral cancer. MGMT expression was declining also undifferentiation, 
tumor thickness and grading. Hence, MGMT expression relates rather to cancer progression 
than to risk. It also seems to indicate a poor prognosis. Unfortunately the study was done on 
a small sample. An involvement of MLH1 gene, being a part of mismatch repair pathway 
early stage of oral cancer, was studied by Gonzales-Ramirez et al. (2010). It was shown that 
gene expression is inhibited by promoter methylation that also located an involvement of 
this gene rather in tumor progression than in risk to develop cancer. 
For such a late stage of oncogenesis as entering metastasis, Sarassin and Kauffman (Sarasin 
& Kauffmann, 2008) put forward hypothesis on association of overexpression of DNA repair 
genes with metastasis. An assumption is that initial genetic instability need in time  
some genetic stabilization provided by over-expression specific DNA repair genes to invade 
and give rise to distant metastasis. To our knowledge the hypothesis has not been  
verified experimentally.  
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A risk of death for head and neck cancer is high for patients with second (multiple) primary 
tumors that encouraged clinical, molecular and genetic studies. Gal et al. (2005) were 
studying polymorphism of such DNA repair genes as XRCC1, XRCC3, XPD and MGMT in 
279 subjects with already diagnosed and treated oral cancer who later on develop second 
primary tumors in upper aerodigestive tract. Polymorphism in XRCC3 241Met was found 
associated with an increased risk of second neoplasm. On the contrary XRCC1 399Gln gene 
was linked to a decreased risk of all-cause mortality in patients with oral cancer. In our 
studies we analyzed an impact of 11 polymorphisms of genes coding two activating 
enzymes, four detoxification enzymes and XPD, XRCC1 and XRCC3 DNA repair enzymes 
in 84 subjects with multiple primary tumors. The results were compared to that in 182 
subjects with a single primary tumors and 143 cancer-free individuals. Looking at an impact 
of a single gene no correlation was found in case of DNA repair genes. The coexistence of 
some genotypes/alleles associated with higher cancer risk was established as an added 
factor for multiple primary tumor development. Our data indicate that the same group of 
low-penetration genes is involved in the development of single and multiple primary head 
and neck cancer, but their association with multiple primary tumor is significantly stronger 
(Rydzanicz, et al., 2005). Significance of NER core gene polymorphism was studied in the 
group of 1376 squamous cell carcinoma head and neck patients. Out of them 110 patients 
developed second primary tumors. None of seven studied genes had a pronounced effect 
for a risk to develop second primary tumors, that to some extent confirms our findings. 
However, the authors suggest that a profile of NER core gene polymorphisms might 
collectively contribute to the risk. 
Nowadays the techniques exploring DNA microarrays technology became available and 
contribute well to the reviewed matter. An example of application of gene expression 
profiling of DNA repair genes is the paper of Rentoft et al. (2009) attempting to differentiate 
a pattern of DNA repair genes involved in development  of head and neck cancer in young 
(<40 years) and elderly subjects. No genes were detected as significantly differentially 
expressed between young and elderly subjects. 
5. Fanconi anemia pathway 
Apart from previously described DNA repair systems present in human cells the Fanconi 
anemia pathway occupies equally important place. Fanconi anemia (FA) represents a 
specific and relatively rare syndrome, primarily described in 1927 by Guido Fanconi 
(Fanconi, 1927) (a Swiss pediatrician). He observed in 3 siblings hereditary form of aplastic 
anemia, panmyelopathy, short stature and hyper-pigmentation, nowadays syndrome 
known as Fanconi anemia. The FA is genetically and phenotypically highly heterogeneous 
condition, whereas patients display a wide variety of abnormalities. Some common features 
attributed to FA are multiple congenital malformations of skeleton and inner organs, radial 
ray defects, abnormal pigmentation and overall altered growth (Alter & Kupfer, 1993). 
However, the most important clinical feature are hematological abnormalities: bone marrow 
failure, aplastic anaemia, myelodysplastic syndrome (MDS), and high proneness to acute 
myeloid leukemia (AML). Besides AML FA patients also carry high risk of developing 
squamous cell carcinomas (SCC), especially of head and neck, gynecological and skin 
tumors (Alter, 1996; Lustig, et al., 1995, Rosenberg, et al., 2003). A considerable part of 
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cancer biology knowledge was described thanks to rare genetic syndromes related with 
cancer proneness such as Fanconi anemia. 
Physiologically, patients with Fanconi anemia demonstrate high susceptibility to cross-
linking agents, which result in significantly increased number of DNA damage events (DNA 
cross-links are most common). As the consequence repair capacity is insufficient to maintain 
DNA integrity. Consequently, the FA pathway is frequently deregulated or inactivated.  
An increased sensitivity of FA patient-derived cells to the lethal effects of numerous cross-
linking agents was described already over three decades ago in mid 70s (Ahmed & Setlow, 
1978; Fujiwara & Tatsumi, 1975). Cloning and cell fusion experiments have so far shown 
existence of fourteen FA complementation groups and corresponding genes (FANCA, B, C, 
D1(BRCA2), D2, E, F, G, I, J(BACH1/BRIP1), L, M, N (PALB2), O(RAD51C), P (SLX4) and 
combined functionally with FA repair pathway (Deakyne et al. 2011; Rego et al.,2009; 
Stoepker et al., 2011). However, their exact role have not yet been completely elucidated. 
The FA-associated genes are not clustered, but dispersed throughout the genome. Next to 
BRCA2 (FANCD1) also BRCA1 was corroborated to be involved in FA and comprises 
another FA associated factor (Garcia-Higuera et al., 2001; Zdzienicka & Arwert, 2002). Thus, 
FA pathway is often called Fanconi/BRCA pathway. 
Complementation group A (mutation in FANCA) stands for majority of the Fanconi anemia 
cases (over 66%), C in 5-15% and G in 5-15% in most of the populations. Only some ethnic 
groups have founder mutation which accounts for most cases of disease (e.g. in Ashkenazi 
Jews mutation IVS4+4 A→T allele). The prevalence of other complementation groups  
is rather rare and many mutations are reported in different Fanconi genes with  
various frequency (Buchwald, 1995; Deakyne et al., 2011; Joenje et al., 1997). The  
open-access database of Fanconi genes mutations is available in the internet 
(http://www.rockefeller.edu/fanconi/mutate). 
The hypothesis over the defect in the repair of damaged DNA is central to the etiology of 
Fanconi anemia. Moreover, recent studies have shown that FA is also clinically related to 
other hereditary chromosomal instability syndromes and the proteins mutated in Bloom 
Syndrome, Nijmegen Breakage Syndrome (NBS), Ataxia Telangiectasia (ATM) and Seckel 
Syndrome (ATR), which are also implicated and crosslink with FA pathway (Andreassen, 
D'Andrea, & Taniguchi, 2004; Nakanishi et al., 2002; Taniguchi et al., 2002). Therefore, an 
emerging body of evidence indicate Fanconi/BRCA DNA repair pathway proteins to 
operate in multiple DNA damage pathways, whereas FA-associated proteins have 
alternative roles. Disruption of any of the genes may lead to arrest of the DNA repair 
processes and accumulation of cancer-proneness events, which finally leads to non-FA 
associated cancer occurrence. Thus, Fanconi pathway appears to play remarkable role in the 
DNA repair capacity of a cell. 
5.1 FA and head and neck cancer 
Numerous clinical data reports, that FA patients demonstrate a high incidence of aggressive 
forms of squamous cell carcinoma, especially at young age, predominantly in head and neck 
sites (HNSCC). The estimated risk is increased over 700 times higher compared to non-FA 
population and rises much above the cumulative risk effect of environmental factors for this 
cancer. Average age of HNSCC patients is usually above 60 years who drink and smoke, in 
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contrast to group so-called “young adults” of age below 40-45 years and not possessed by 
habits. Interestingly, FA patients are usually non-smokers and non-drinkers and 
demonstrate higher risk of HNSCCs with 40% cumulative incidence by the age of 40 years 
with 2-year survival rate much below 50% (Kutler et al., 2003). Seemingly, FA –associated 
squamous carcinoma of head and neck do not differ considerably from sporadic HNSCC, 
except hypersensitivity to crosslinking agents. FA/HNSCC patients are more vulnerable to 
the exposition of oral squamous mucosa as a first line absorbing carcinogens. Therefore, 
predominant site of cancer occur in oral cavity, oropharynx and tounge which is a major 
cause of high mortality in these patients. The repair of ICLs is mainly driven during cell 
arrest in late S/G2 phase. G2 phase is noticeable prolonged and, thus it rise the risk of viral 
infections, particularly Epstein–Barr virus (EBV) and oncogenic types of human papilloma 
virus (HPV). They integrate preferably to damaged sites of DNA. In previous study of 
FA/HNSCC over 80% have been infected with HPV (none of these showed mutation in 
TP53) in respect to 36% in non-FA HNSCC patients (Kutler et al., 2003). However, other 
studies could not demonstrate such high differences, but the disproportion was undisputed. 
Noteworthy is also that younger patients characterize with distinct sexual behavior, with 
higher preference to oral sex and thus high prediction of being HPV positive (Lustig et al., 
1995; Rosenberg, Alter, & Ebell, 2008).  
FA/HNSCC patients undergo strictly modified cancer therapy, eliminating ICLs inducers. 
Hematopoietic stem cell transplant (SCT) is nowadays the only efficient treatment  
for direct restoration of blood cells production in Fanconi anemia patients. There have 
been much of difficulties to optimize SCT protocols because of high toxicity of procedure 
to patients. From the other, side heavy SCT conditioning is frequently a cause of  
induction of squamous cell carcinomas, particularly head and neck cancers (Alter, 2005; 
Rosenberg et al., 2005). 
It has been also suggested that single unrepaired ICLs in FA patients may be enough to 
promote the translocation of oncogenes or the deletion of tumour suppressor genes. 
Moreover, specific and well known oncogenic translocations such as loss of 1q, 3q or 9p and 
seems to be favored in FA (Sala-Trepat, et al., 1993; Tonnies et al., 2003). 
5.2 DNA cross-linkers 
As previously mentioned DNA in Fanconi anemia patients undergoes damage mostly by 
exposition to cross-linkers. Interstrand crosslinks (ICLs) are extremely toxic DNA damage 
type. Many drugs (mainly alkylating agents) producing interstrand cross-links in cellular 
DNA have been commonly used in clinical chemotherapy of solid and hematological 
malignancies. The idea of usage of crosslinkers to treat cancer was born out of horror of the 
Second World War. The autopsies of victims killed with chemical weapons (e.g. sulphur 
mustard) have shown selectively attacked blood white cells. The hypothesis has been 
established that those chemicals could have been useful for the treatment of leukemia 
(Deans & West, 2011) and further to other cancers. These include the nitrogen mustard class 
in use until now (e.g. melphalan, cyclophosphamide, chlorambucil etc), natural compounds: 
(mitomycin C, psoralen, aldehydes, formaldehydes),  platinum drugs (cisplatin, carboplatin, 
oxaliplatin). Some physical agents such as UV light exposure or reactive oxygen species 
(ROS) are also capable to induce ICLs. Platinums and nitrogen mustard class require two 
active leaving groups, which are absorbed inside the cell by the sequential displacement of 
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chloride ions by H2O molecules. This active form predominantly crosslink DNA at N7-
position of guanosine or adenosine on the opposite strands and forming ICLs. Mitomycin C 
and psoralens contain planar rings that must be activated by photon-mediated 
cycloaddition or cycloreduction, and attack DNA bases. The covalent bounds between two 
strands of DNA produced by cross-linkers leads to inhibition of fundamental processes such 
as replication and protein biosynthesis, preventing unwind for polymerase access. 
Clustering both DNA strands significantly reduces ability of DNA repair machinery to 
operate, and repair of cross-link involve a highly complexed networks. At the higher 
structural rank this cause high chromosomal instability (Bauer et al., 2008).  
Noteworthy, major FA diagnostic method is still based on the cytogenetic analysis of 
lymphocytes that have been treated with ICL-inducing agents (MMC or DEB cross-linker) 
where chromosomal breaks are counted. As result, FA cells demonstrate highly increased 
levels of chromosome aberrations, such as: chromosome breakages and radical  forms of 
chromosomes (Auerbach, 1988; Li et al., 1999). 
5.3 DNA repair by FA/BRCA pathway 
FA/BRCA pathway is currently conceived as the coordinator of several repair systems, 
including homologous recombination (HR), nucleotide excision repair (NER) and 
translesion synthesis (TLS). However, a major pathway for the repair of DNA interstrand 
cross-links (ICLs) is homologous recombination (also known as homology-directed repair, 
HDR). Postulated and partially elucidated model of FA processing with ICL repair begins 
when the replication forks are stalked and lesion recognition replication protein A (RPA) is 
recruited and responsible for stabilizing and coating of single DNA strands (L. C. Wang, 
Stone, Hoatlin, & Gautier, 2008). ICL invokes also FANCM with associated proteins (RMI 1 
and RMI 2) which leads to the assemble of FA core complex (FANCA,B,C,E,F,G,L, M and 
N). FANCM also recruits the Bloom’s syndrome complex (BTR), and cooperates with RPA 
protein. This activates checkpoint ataxia telangiectasia kinase ATR and its downstream 
effector kinase CHK1 and Rad3-related (ATR)–CHK1 signalling cascade. ATR and CHK1 
phosphorylate several components of the core complex in order to activate them. UBE2T, 
the ubiquitin-conjugating enzyme (E2) binds to FANCL, the ubiquitin ligase subunit of the 
core complex. Activate core complex monoubiquitinate FANCD2 and FANCI (ID complex) 
a key event in FA pathway. BRCA1 and BRCA2 complex initiates homologous 
recombination and stabilizes the stalled replication fork. Monoubiquitinated FANCD2 forms 
DNA damage inducible foci together with core complex and several other downstream FA-
associated DNA repair proteins such as: structure-specific nucleases and translesion 
polymerases, MRN complex (MRE11, NBN, RAD50), BRIP1, PALB2, FANCO and further 
participate and cooperate in ICL removal (Fig.2). Homologous recombination is performed 
on the basis of homologous sequence on sister chromatids and the mechanism in itself is 
similar to crossing-over during meiosis (Deakyne et al., 2011,; Guervilly et al 2008; Machida 
et al., 2006; Rego et al., 2009; Takata et al., 2009). 
5.4 Disruption of FA/BRCA pathway in HNSCC 
The DNA damage response pathway controlled by the Fanconi anemia/BRCA pathway 
genes can be disrupted by either genetic or epigenetic events. 
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Most FA-associated genes have a wide variety of mutations in FA/HNSCC patients and  
include deletions, frameshifts, stop codons, splice-site mutations and missense mutations. 
 
Fig. 2. Exemplary model of FA/BRCA pathway. 
At this point of limited evidence, it seems that heterozygosity for any of FA gene mutation 
except BRCA2 generates higher susceptibility to cancer, whereas biallelic mutation in single 
FA genes contribute to earlier cancer development and generally poorer prognosis. 
However, no specific mutations have been associated with head and neck cancer. Some 
array-based data (Sparano et al., 2006) demonstrates the copy number alterations (CNA) in 
regions covering FA genes BRCA1, BRCA2, FANCD2, and FANCG but no direct associations 
with the disease were found. In contrast, FANCA has been analyzed in arrayCGH-based 
study (Bauer et al., 2008), where the region 16q23–q24 (FANCA locus) showed a significant 
gain associated with lower survival rates in HNSCC patients. 
Epigenetic mechanisms such as DNA methylation, a main posttranscriptional DNA 
regulation plays a predominant role in majority of developmental processes and regulates 
expression of most genes. Moreover, it maintains integrity of chromatin through stabilizing 
its structure. DNA methylation level is usually measured by methyl groups attached to 
position 5 in pyrimidine ring of cytosines. 
Somatic inactivation of the FA pathway by epigenetic silencing has been observed in several 
different types of sporadic cancer (Lyakhovich & Surralles, 2006), such as bladder cancer 
(Neveling et al., 2007), ovarian cancer (Lim et al., 2008), breast cancer (Wu, Shin-ya, & Brosh, 
2008) cervical cancer (Narayan et al., 2004) and of course in HNSCC (Marsit et al., 2004; 
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Szaumkessel et al., 2011 ; Wreesmann et al., 2007). Our own study has demonstrated the 
disruption of DNA methylation of promoter region in FANCA, BRCA1 and BRCA2 in 
squamous laryngeal carcinoma cell lines and primary tumors (Szaumkessel et al., 2011). 
BRIP1 and FANCB have been shown to be higher and more frequently methylated 
compared to normal mucosa (Smith et al., 2010). FANCB is suggested to play important role 
in HNSCC pathogenesis as the hypermethylation was detected almost exclusively in 
cancerous samples. In other study (Wreesmann et al., 2007) FANCB, FANCF, FANCJ and 
FANCM were demonstrated to be affected by downregulation in HNSCC, however no 
methylation changes has been found comparing to non-tumor controls. FANCF promotoric 
DNA hypermethylation was demonstrated to be associated with smoking habit as the 
established risk factor in HNSCC (Marsit et al., 2004) but with no further reflection in  
other studies. 
Recent years FA pathway is becoming of high interest because of versatile nature in respect 
to DNA repair. This would suggest that FA genes might be potentially widely used targets 
for future therapies of head and neck. Specific mutations or/and known deregulation 
mechanisms could provide a knowledge in order to design a targeted drugs to enhance 
existing anti-cancer therapies. 
6. Summary 
Despite the action upon improving the classical surgery and radio- and chemotherapy, a 
genetic background plays the supportive role and promise a significant enhancement in 
prevention and/or head and neck cancer curability. Last years has brought much of 
understanding in HNSCC biology, whereas many markers have been identified and utilized 
for genetic testing and therapies. Modern high-resolution techniques (e.g. CGH, aCGH, 
microarrays) has pointed relatively important DNA hotspots and greatly contributed to 
overall knowledge. However, the pathogenesis of HNSCC seems to be still elusive and 
ambiguous. The expectations always rise together with emerging new technologies and 
promise to develop brand new anti-cancer therapies. 
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